| Autor: |
Kim T; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA., James BT; Computer Science and Artificial intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kahn MC; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA., Blanco-Duque C; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA., Abdurrob F; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA., Islam MR; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA., Lavoie NS; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA., Kellis M; Computer Science and Artificial intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Tsai LH; Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA. |
| Abstrakt: |
Patients with cancer undergoing chemotherapy frequently experience a neurological condition known as chemotherapy-related cognitive impairment, or "chemobrain," which can persist for the remainder of their lives. Despite the growing prevalence of chemobrain, both its underlying mechanisms and treatment strategies remain poorly understood. Recent findings suggest that chemobrain shares several characteristics with neurodegenerative diseases, including chronic neuroinflammation, DNA damage, and synaptic loss. We investigated whether a noninvasive sensory stimulation treatment we term gamma entrainment using sensory stimuli (GENUS), which has been shown to alleviate aberrant immune and synaptic pathologies in mouse models of neurodegeneration, could also mitigate chemobrain phenotypes in mice administered a chemotherapeutic drug. When administered concurrently with the chemotherapeutic agent cisplatin, GENUS alleviated cisplatin-induced brain pathology, promoted oligodendrocyte survival, and improved cognitive function in a mouse model of chemobrain. These effects persisted for up to 105 days after GENUS treatment, suggesting the potential for long-lasting benefits. However, when administered to mice 90 days after chemotherapy, GENUS treatment only provided limited benefits, indicating that it was most effective when used to prevent the progression of chemobrain pathology. Furthermore, we demonstrated that the effects of GENUS in mice were not limited to cisplatin-induced chemobrain but also extended to methotrexate-induced chemobrain. Collectively, these findings suggest that GENUS may represent a versatile approach for treating chemobrain induced by different chemotherapy agents. |
